<DOC>
	<DOCNO>NCT02842320</DOCNO>
	<brief_summary>The tyrosine kinase inhibitor therapy ( iTKs ) first-line treatment chronic myelogenous leukemia ( CML ) . Its effectiveness control progression disease possible today consider stop treatment patient deep molecular response ( &gt; RM4.0 ) . Only 50 % case , patient relapse . It show patient hematopoietic stem cell ( HSCs ) persistant , quiescent insensitive iTKs . These cell probably origin relapse . It therefore necessary develop complementary therapy cure disease consider discontinuation iTKs The development anti-tumor immunotherapy approach use genetically modify T cell express chimeric antigen receptor ( CAR ) specifically target CML CSH + could address issue . The membrane expression IL-1-RAP protein could interest target .</brief_summary>
	<brief_title>Targeting Leukemic Stem Cell Expressing IL-1RAP Protein Chronic Myelogenous Leukemia ( CML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>patient strong suspicion CML diagnose part routine activity . write informed consent patient atypical CML patient non SMP CML patient previously treat interferon patient enrol another study therapy within exclusion period thereof pregnant breastfeed woman patient guardianship , curator protection justice .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>